The Survey Research and Data Acquisition Resource (SRDAR) is a new CCSG Resource that originated out of the Cancer Prevention and Population Sciences Program in the summer of 2004. The mission of SRDAR is to provide a collaborative Resource within RPCI for data collection and study design services for investigators from CCSG Programs. Collecting valid and reliable survey data is critical for all investigators. SRDAR data collection services include phone surveys, face-to-face interviews, clinical followup assessments, trial recruitment, web-based surveys, mail-based biologic data collection, scannable forms and focus groups. SRDAR can also provide assistance with protocol development and dissemination of findings. The personnel structure includes the Resource Director, scientific coordinator, administrative coordinator, informatics coordinator and data collection staff (currently 30 FTE). Leading up to the designation as a CCSG Resource, RPCI contributed $167,520 in personnel and equipment expenses to create the SRDAR infrastructure. CCSG support will be used to defray these management expenses and chargebacks will cover 66% of the expected $1.1 million FY 2008 operating budget. Since its inception, SRDAR has supported 41 projects and generated $1.1 million in revenue;51% has come from peerreviewed sources, including 40% from NIH grants. As a CCSG Resource, SRDAR will seek to expand its role in research in all CCSG Programs. The Resource is used by two Programs and 88% of users are CCSG members. $98,966 in CCSG support is requested, representing 9% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-35
Application #
8296649
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
35
Fiscal Year
2011
Total Cost
$225,600
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440
Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652
Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940
Merzianu, Mihai; Groman, Adrienne; Hutson, Alan et al. (2018) Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study. Am J Clin Pathol 150:393-405
Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Muramatsu, Masashi; Akakura, Shin; Gao, Lingqiu et al. (2018) SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget 9:33515-33527
Kumar, Sandeep; Inigo, Joseph R; Kumar, Rahul et al. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82-93
Liu, Chunhong; Yu, Tao; Xing, Zhuo et al. (2018) Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. Oncotarget 9:4773-4786
Cimato, Thomas R; Conway, Alexis; Nichols, Julianne et al. (2018) CD133 expression in circulating hematopoietic progenitor cells. Cytometry B Clin Cytom :

Showing the most recent 10 out of 1555 publications